{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:17:23Z","timestamp":1791307043984,"version":"4.3.1"},"reference-count":24,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We evaluated a treatment strategy targeting both lymphoma cells (by rituximab) and the microenvironment (by thalidomide) in 16 patients with relapsed\/refractory mantle cell lymphoma (MCL). Rituximab was administered at 375 mg\/m2 for 4 weekly doses concomitantly with thalidomide (200 mg daily, with a dose increment to 400 mg on day 15), which was continued as maintenance therapy until progression\/relapse. Thirteen patients (81%) experienced an objective response, with 5 complete responders (31%). Median progression-free survival (PFS) was 20.4 months (95% confidence interval [CI], 17.3-23.6 months), and estimated 3-year survival was 75%. In patients achieving a complete response, PFS after rituximab plus thalidomide was longer than PFS after the preceding chemotherapy. Severe adverse events included 2 thromboembolic events and 1 grade IV neutropenia associated with thalidomide. Our results suggest that rituximab plus thalidomide has marked antitumor activity in relapsed\/refractory MCL and a low toxicity profile, which warrants further evaluation in MCL.<\/jats:p>","DOI":"10.1182\/blood-2004-03-1091","type":"journal-article","created":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:13:21Z","timestamp":1086048801000},"page":"2269-2271","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":129,"title":["Antitumor activity of rituximab plus thalidomide in patients with relapsed\/refractory mantle cell lymphoma"],"prefix":"10.1182","volume":"104","author":[{"given":"Hannes","family":"Kaufmann","sequence":"first","affiliation":[{"name":"From the Department of Medicine I, Clinical Division of Oncology, University Hospital Vienna; the Department of Medicine IV, University Hospital Vienna; the Department of Radiology, University Hospital Vienna; and the Department of Pathology, University Hospital Vienna, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Raderer","sequence":"additional","affiliation":[{"name":"From the Department of Medicine I, Clinical Division of Oncology, University Hospital Vienna; the Department of Medicine IV, University Hospital Vienna; the Department of Radiology, University Hospital Vienna; and the Department of Pathology, University Hospital Vienna, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Wo\u0308hrer","sequence":"additional","affiliation":[{"name":"From the Department of Medicine I, Clinical Division of Oncology, University Hospital Vienna; the Department of Medicine IV, University Hospital Vienna; the Department of Radiology, University Hospital Vienna; and the Department of Pathology, University Hospital Vienna, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Pu\u0308spo\u0308k","sequence":"additional","affiliation":[{"name":"From the Department of Medicine I, Clinical Division of Oncology, University Hospital Vienna; the Department of Medicine IV, University Hospital Vienna; the Department of Radiology, University Hospital Vienna; and the Department of Pathology, University Hospital Vienna, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Bankier","sequence":"additional","affiliation":[{"name":"From the Department of Medicine I, Clinical Division of Oncology, University Hospital Vienna; the Department of Medicine IV, University Hospital Vienna; the Department of Radiology, University Hospital Vienna; and the Department of Pathology, University Hospital Vienna, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Zielinski","sequence":"additional","affiliation":[{"name":"From the Department of Medicine I, Clinical Division of Oncology, University Hospital Vienna; the Department of Medicine IV, University Hospital Vienna; the Department of Radiology, University Hospital Vienna; and the Department of Pathology, University Hospital Vienna, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Chott","sequence":"additional","affiliation":[{"name":"From the Department of Medicine I, Clinical Division of Oncology, University Hospital Vienna; the Department of Medicine IV, University Hospital Vienna; the Department of Radiology, University Hospital Vienna; and the Department of Pathology, University Hospital Vienna, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Drach","sequence":"additional","affiliation":[{"name":"From the Department of Medicine I, Clinical Division of Oncology, University Hospital Vienna; the Department of Medicine IV, University Hospital Vienna; the Department of Radiology, University Hospital Vienna; and the Department of Pathology, University Hospital Vienna, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021218094083600_REF1","unstructured":"Campo E, Raffeld M, Jaffe ES. Mantle-cell lymphoma. Semin Hematol. 1999;36: 115-126."},{"key":"2020021218094083600_REF2","doi-asserted-by":"crossref","unstructured":"Hiddemann W, Unterhalt M, Herrmann R, et al. Mantle cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. J Clin Oncol. 1998;16: 1922-1930.","DOI":"10.1200\/JCO.1998.16.5.1922"},{"key":"2020021218094083600_REF3","doi-asserted-by":"crossref","unstructured":"Freedman A, Neuberg D, Gribben J, et al. High-dose chemo-radiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle cell lymphoma: no evidence for long-term remission. J Clin Oncol. 1998;16: 13-18.","DOI":"10.1200\/JCO.1998.16.1.13"},{"key":"2020021218094083600_REF4","doi-asserted-by":"crossref","unstructured":"Gopal AK, Rajendran JG, Petersdorf SH, et al. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood. 2002;99: 3158-3162.","DOI":"10.1182\/blood.V99.9.3158"},{"key":"2020021218094083600_REF5","doi-asserted-by":"crossref","unstructured":"Manabe A, Murti KG, Coustan-Smith E, et al. Adhesion-dependent survival of normal and leukemic human B lymphoblasts on bone marrow stromal cells. Blood. 1994;83: 758-766.","DOI":"10.1182\/blood.V83.3.758.758"},{"key":"2020021218094083600_REF6","doi-asserted-by":"crossref","unstructured":"Merville P, Dechanet J, Desmouliere A, et al. Bcl-2+ tonsillar plasma cells are rescued from apoptosis by bone marrow fibroblasts. J Exp Med. 1996;183: 227-236.","DOI":"10.1084\/jem.183.1.227"},{"key":"2020021218094083600_REF7","doi-asserted-by":"crossref","unstructured":"Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341: 1565-1571.","DOI":"10.1056\/NEJM199911183412102"},{"key":"2020021218094083600_REF8","doi-asserted-by":"crossref","unstructured":"Strasser K, Ludwig H. Thalidomide treatment in multiple myeloma. Blood Rev. 2002;16: 207-215.","DOI":"10.1016\/S0268-960X(02)00031-0"},{"key":"2020021218094083600_REF9","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Zomas A, Viniou NA, et al. Treatment of Waldenstrom's macroglobulinemia with thalidomide. J Clin Oncol. 2001;19: 3596-3601.","DOI":"10.1200\/JCO.2001.19.16.3596"},{"key":"2020021218094083600_REF10","doi-asserted-by":"crossref","unstructured":"Foran JM, Cunningham D, Coiffier B, et al. Treatment of mantle cell lymphoma with rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response. Ann Oncol. 2000;11: 117-121.","DOI":"10.1093\/annonc\/11.suppl_1.S117"},{"key":"2020021218094083600_REF11","doi-asserted-by":"crossref","unstructured":"Cheson B, Horning S, Coiffier B, et al. Report of an International Workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol. 1999;17: 1244-1253.","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"2020021218094083600_REF12","doi-asserted-by":"crossref","unstructured":"Damaj G, Lefrere F, Delarue R, Varet B, Furman R, Hermine O. Thalidomide therapy induces response in relapsed mantle cell lymphoma. Leukemia. 2003;17: 1914-1915.","DOI":"10.1038\/sj.leu.2403058"},{"key":"2020021218094083600_REF13","doi-asserted-by":"crossref","unstructured":"Urbauer E, Kaufmann H, No\u0308sslinger T, Raderer M, Drach J. Thromboembolic events during treatment with thalidomide. Blood. 2002;99: 4247-4248.","DOI":"10.1182\/blood-2001-12-0245"},{"key":"2020021218094083600_REF14","unstructured":"Coiffier B, Haioun N, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998;92: 1927-1932."},{"key":"2020021218094083600_REF15","doi-asserted-by":"crossref","unstructured":"Ghielmini M, Schmitz SF, Burki K, et al. The effect of rituximab on patients with follicular and mantle cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol. 1999;11(suppl 1): S123-S126.","DOI":"10.1093\/annonc\/11.suppl_1.S123"},{"key":"2020021218094083600_REF16","unstructured":"Dreyling MH, Forstpointner R, Repp R, et al. Combined immuno-chemotherapy (R-FCM) results in superior remission and survival rates in recurrent follicular and mantle cell lymphoma: final results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG) [abstract]. Blood. 2003;102: 103a. Abstract no. 351."},{"key":"2020021218094083600_REF17","doi-asserted-by":"crossref","unstructured":"Wilson EA, Jobanputra R, Jackson R, Parker AN, McQuaker IG. Response to thalidomide in chemotherapy-resistant mantle cell lymphoma: a case report. Br J Haematol. 2002;119: 128-130.","DOI":"10.1046\/j.1365-2141.2002.03810.x"},{"key":"2020021218094083600_REF18","doi-asserted-by":"crossref","unstructured":"Raje N, Anderson K. Thalidomide, a revival story. N Engl J Med. 1999;341: 1606-1609.","DOI":"10.1056\/NEJM199911183412110"},{"key":"2020021218094083600_REF19","doi-asserted-by":"crossref","unstructured":"Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol. 1999;163: 380-386.","DOI":"10.4049\/jimmunol.163.1.380"},{"key":"2020021218094083600_REF20","unstructured":"Settles B, Stevenson A, Wilson K, et al. Down-regulation of cell adhesion molecules LFA-1 and ICAM-1 after in vivo treatment with the anti-TNF-alpha agent thalidomide. Cell Mol Biol. 2001;47: 1105-1114."},{"key":"2020021218094083600_REF21","doi-asserted-by":"crossref","unstructured":"Haslett PAJ, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med. 1998;187: 1885-1892.","DOI":"10.1084\/jem.187.11.1885"},{"key":"2020021218094083600_REF22","doi-asserted-by":"crossref","unstructured":"Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001;98: 210-216.","DOI":"10.1182\/blood.V98.1.210"},{"key":"2020021218094083600_REF23","doi-asserted-by":"crossref","unstructured":"Selenko N, Maidic O, Draxier S, et al. CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells. Leukemia. 2001;15: 1619-1626.","DOI":"10.1038\/sj.leu.2402226"},{"key":"2020021218094083600_REF24","doi-asserted-by":"crossref","unstructured":"D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994;91: 4082-4085.","DOI":"10.1073\/pnas.91.9.4082"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/104\/8\/2269\/1702532\/zh802004002269.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/104\/8\/2269\/1702532\/zh802004002269.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T14:59:30Z","timestamp":1705157970000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/104\/8\/2269\/19072\/Antitumor-activity-of-rituximab-plus-thalidomide"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10,15]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2004,10,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2004-03-1091","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,10,15]]}}}